Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion.
OBJECTIVE
Management of lymph nodes in radiotherapy for prostate cancer is an issue for curative intent. To find the influence of lymph nodes, patients with T1-T3 prostate cancer and surgically confirmed negative nodes were treated with radiotherapy.


METHODS
After lymphadenectomy, 118 patients received photon beam radiotherapy with 66 Gy to the prostate. No adjuvant treatment was performed until biochemical failure. After failure, hormone therapy was administered. Follow-up period was 57 months (mean).


RESULTS
Biochemical failure occurred in 47 patients. Few failures were observed in patients with low (24%) and intermediate risks (14%). In contrast, 64% of high-risk patients experienced failure, 97% of whom showed until 36 months. Most patients with failure responded well to hormone therapy. After 15 months (mean), a second biochemical failure occurred in 21% of patients who had the first failure, most of them were high risk. Factors involving failure were high initial and nadir prostate-specific antigen, advanced stage, short prostate-specific antigen-doubling time and duration between radiation and first failure. Failure showed an insufficient reduction in prostate-specific antigen after radiotherapy. Factor for second failure was prostate-specific antigen-doubling time at first failure.


CONCLUSIONS
Half of high-risk patients experienced biochemical failure, indicating one of the causes involves factors other than lymph nodes. Low-, intermediate- and the other half of high-risk patients did not need to take immediate hormone therapy after radiotherapy. After failure, delayed hormone therapy was effective. Prostate-specific antigen parameters were predictive factors for further outcome.
Suzuki
Noriyuki
N
Department of Urology, Asahi General Hospital, Asahi, Chiba, Japan.
Shimbo
Masaki
M
Amiya
Yoshiyasu
Y
Tomioka
Susumu
S
Shima
Takayuki
T
Murakami
Shino
S
Nakatsu
Hiroomi
H
Oota
Sayako
S
Shimazaki
Jun
J
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
BJU Int. 2008 Dec;102(11):1589-93
18710447
Eur Urol. 2009 Jun;55(6):1251-65
19297079
Urol Clin North Am. 2001 Aug;28(3):491-8
11590808
J Urol. 2007 Mar;177(3):916-20
17296375
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):975-81
16750319
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):39-45
8270458
Eur J Surg Oncol. 2009 Feb;35(2):123-8
18786800
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):695-701
15708247
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1344-9
19464821
Cancer. 2001 Jan 1;91(1):66-73
11148561
Cancer. 2008 Jan 1;112(1):55-60
17968996
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):437-41
17881145
Eur Urol. 2007 Oct;52(4):1044-50
17197071
J Urol. 2008 Sep;180(3):898-902; discussion 902-3
18635222
Urology. 2001 Dec;58(6):843-8
11744442
Cancer. 2009 Jun 1;115(11):2388-99
19399748
Cancer. 1993 Mar 15;71(6):2031-40
7680277
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10
15752879
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1474-82
15964706
Cancer. 2009 Aug 1;115(15):3446-56
19484790
Strahlenther Onkol. 2009 Jul;185(7):438-45
19714305
Cancer. 2009 Oct 1;115(19):4477-87
19691097
Cancer. 1993 Sep 1;72(5):1709-25
7688659
JAMA. 1998 Sep 16;280(11):969-74
9749478
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7
7505775
Am J Surg Pathol. 2005 Sep;29(9):1228-42
16096414
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):104-9
19286330
Cancer. 2007 Jul 1;110(1):68-80
17520705
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):782-91
19014779